TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22800378

Group type: EXPERIMENTAL
Intervention: Department of Geriatrics (DG) treatment pathway including comprehensive geriatric assessment, pain relief, hydration, oxygenation, nutrition, elimination, prevention and management of delirium, assessment of falls and osteoporosis, early mobilization, and individualized rehabilitation plans.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment in the Department of Orthopaedic Surgery (DOS).
Number of subjects: 0
Study: 19841897

Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (0.01-0.03 U/min)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Norepinephrine infusion (5-15 microg/min)
Number of subjects: 778
Study: 17478939

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg intravenously twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no ranitidine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranitidine treatment group
Number of subjects: 30
Study: 16983112

Group type: EXPERIMENTAL
Intervention: Exatecan plus gemcitabine (exatecan 2.0 mg/m2 and gemcitabine 1,000 mg/m2 on days 1 and 8, every 3 weeks)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Gemcitabine alone (1,000 mg/m2 up to 7 weeks in the first cycle, then once a week for the first 3 weeks of a 4‐week cycle)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Exatecan plus gemcitabine
Number of subjects: 349

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 349
Study: 12586182

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Carteolol 2% twice daily and Pilocarpine 2% twice daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Carteolol plus Pilocarpine
Number of subjects: 51
Study: 10545432

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Propranolol, verapamil, and procainamide
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 79
Study: 8568135

Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy with allergen in powder form
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 1992259

Group type: EXPERIMENTAL
Intervention: 1:100,000 epinephrine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 92
Study: 6889140

Group type: EXPERIMENTAL
Intervention: Elixophyllin 400 mg capsule
Number of subjects: 18

Group type: COMPARATOR
Intervention: Elixophyllin 373 mg elixir
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Theolair 375 mg tablet
Number of subjects: 18
Study: 30971235

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) added to high-dose corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to high-dose corticosteroids
Number of subjects: 0
Study: 26160253

Group type: EXPERIMENTAL
Intervention: Aggressive early feeding guidelines (enteral and parenteral nutrition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late-onset sepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrient intakes in week 1
Number of subjects: 0
Study: 26130358

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (the Exeter Trauma Stem)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Internal fixation using the Targon Femoral Plate
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 24103901

Group type: EXPERIMENTAL
Intervention: PHEN 7.5 mg/TPM ER 46 mg (7.5/46)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: PHEN 15 mg/TPM ER 92 mg (15/92)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 22936157

Group type: EXPERIMENTAL
Intervention: 1KTWT (1-km treadmill walking test)
Number of subjects: 178
Study: 18773214

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 17579200

Group type: EXPERIMENTAL
Intervention: VA2914 (5 mg/d)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: VA2914 (10 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 46
Study: 15222526

Group type: EXPERIMENTAL
Intervention: Tinospora crispa (1 gram thrice daily for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12667338

Group type: EXPERIMENTAL
Intervention: S + R (surgery plus radiotherapy)
Number of subjects: 495

Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 495
Study: 10575335

Group type: EXPERIMENTAL
Intervention: 1% halothane
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1.5% isoflurane
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intravenous anesthesia without volatile anesthetics
Number of subjects: 27
Study: 7568654

Group type: EXPERIMENTAL
Intervention: Group therapy (8 sessions)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group therapy plus consultation
Number of subjects: 70
Study: 2291838

Group type: EXPERIMENTAL
Intervention: Metformin 1.0 g/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin 2.0 g/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6796885

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine plus Oxygen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31919919

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 weeks)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 30608515

Group type: EXPERIMENTAL
Intervention: Cancer screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 0
Study: 27930939

Group type: EXPERIMENTAL
Intervention: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 2.6 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 5.3 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT)
Number of subjects: 125
Study: 25414250

Group type: EXPERIMENTAL
Intervention: Multiple-family intervention (n=48)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Single-family intervention (n=49)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both treatment groups pooled
Number of subjects: 97
Study: 23964994

Group type: EXPERIMENTAL
Intervention: benfotiamine 900 mg/day for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo for 6 weeks
Number of subjects: 22
Study: 21971774

Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study: 18310262

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori test and treat (H pylori 13C urea breath test plus one week of eradication treatment if positive)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) alone
Number of subjects: 699
Study: 16990573

Group type: EXPERIMENTAL
Intervention: Fathers died at <65 years
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Fathers alive at 65 years but died by 80 years
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Fathers alive at 80 years
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Mean common carotid arteries intima-media thickness in subjects with premature paternal death
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Mean PWV in the 3 groups of paternal longevity
Number of subjects: 1117
Study: 14566995

Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High fat and protein breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Typical breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 24
Study: 11039005

Group type: EXPERIMENTAL
Intervention: Auricular-plaster therapy plus acupuncture at Zusanli (ST 36)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study: 8721275

Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxisylyte
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intracavernous administration of moxisylyte without a tourniquet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intracavernous administration of moxisylyte with a tourniquet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Total percentages of metabolites recovered in urine after i.v. administration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Total percentages of metabolites recovered in urine after i.c. administration without a tourniquet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Total percentages of metabolites recovered in urine after i.c. administration with a tourniquet
Number of subjects: 18
Study: 1443353

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1-g single dose 30 minutes before surgery)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Cefoxitin (1-g dose 30 minutes before surgery and 1 g every 6 hours for 24 hours, total dose 4 g)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Cefazolin (1-g dose 30 minutes before surgery, followed by 1 g every 8 hours for 48 hours, total dose 6 g)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Cefotaxime and Cefazolin
Number of subjects: 273
Study: 3904673

Group type: EXPERIMENTAL
Intervention: Polyester antimicrobial incise drape (loban 2 Antimicrobial Film) with one-minute skin preparation using 70% alcohol or 2% iodine in 90% alcohol
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Standard ten-minute skin preparation with Betadine
Number of subjects: 1324
Study: 31679112

Group type: EXPERIMENTAL
Intervention: Asunercept plus reirradiation (rRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reirradiation (rRT) alone
Number of subjects: 0
Study: 29244026

Group type: EXPERIMENTAL
Intervention: Pimodivir 1,200/600 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Pimodivir (all groups)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 27062157

Group type: COMPARATOR
Intervention: Room air breathing (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Breathing 18% O2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Breathing 14% O2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Breathing 12.5% O2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution (Low [Hb])
Number of subjects: 10
Study: 25080605

Group type: EXPERIMENTAL
Intervention: LAUNCH with home visit (LAUNCH-HV)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LAUNCH-clinic
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pediatrician counseling (PC)
Number of subjects: 33
Study: 22486142

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ketamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous infusion of morphine (control)
Number of subjects: 45
Study: 20360429

Group type: EXPERIMENTAL
Intervention: Systemic low-dose aspirin (81 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Systemic clopidogrel (75 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No systemic drug (ND)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Localized COX inhibition (ketorolac)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitric oxide synthase inhibition (NOS-I)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NOS-I+COX-I
Number of subjects: 10

Group type: COMPARATOR
Intervention: Time to increase Tor 1 degrees C
Number of subjects: 10
Study: 18622831

Group type: EXPERIMENTAL
Intervention: 1.0 vol% 3-acryloyloxypropyltrimethoxysilane + 0.3 vol% 1,2-bis-(triethoxysilyl)ethane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cimaratrade mark silane (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.0 vol% 3-acryloyloxypropyltrimethoxysilane + 0.1 vol% 1,2-bis-(triethoxysilyl)ethane
Number of subjects: 20
Study: 17954642

Group type: EXPERIMENTAL
Intervention: CT venography (CTV)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Combined CT venography (CTV) and CT angiography (CTA)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Combined CT angiography (CTA) and sonography
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Patients with signs or symptoms of DVT
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Patients with a history of DVT
Number of subjects: 711
Study: 15650347

Group type: EXPERIMENTAL
Intervention: Recruitment protocol for HIV/STI prevention study
Number of subjects: 217
Study: 11302304

Group type: EXPERIMENTAL
Intervention: 30 mg sodium hyaluronate
Number of subjects: 226

Group type: COMPARATOR
Intervention: physiologic saline (control)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Number of subjects: 226

Group type: COMPARATOR
Intervention: saline
Number of subjects: 226
Study: 9288374

Group type: EXPERIMENTAL
Intervention: Oxygen via a facemask at 4 l/min
Number of subjects: 100

Group type: COMPARATOR
Intervention: No oxygen
Number of subjects: 100
Study: 8323999

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (BC-PS) 300 mg/day for 6 months
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 3521254

Group type: EXPERIMENTAL
Intervention: Formulas I and V providing 13 g protein and 350 kcal per day
Number of subjects: 3

Group type: COMPARATOR
Intervention: Unsupplemented group (control)
Number of subjects: 3
Study: 30803326

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice bag)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham treatment (room-temperature bag)
Number of subjects: 22
Study: 30236308

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2661

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2661
Study: 27537244

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24398818

Group type: EXPERIMENTAL
Intervention: Fentanyl and bupivacaine combinations
Number of subjects: 300
Study: 22382053

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) with Shared Decision Making intervention
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 187
Study: 18980622

Group type: EXPERIMENTAL
Intervention: DMSO-depleted autografts
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unmanipulated autografts
Number of subjects: 53
Study: 17617270

Group type: EXPERIMENTAL
Intervention: TMC125 (etravirine) 200 mg twice daily
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: TMC125 (etravirine)
Number of subjects: 612
Study: 15204275

Group type: EXPERIMENTAL
Intervention: 15-min nap during post-lunch rest period
Number of subjects: 8

Group type: COMPARATOR
Intervention: No nap during the no-nap week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Follow-up week where subjects determined whether or not to nap
Number of subjects: 8
Study: 11756100

Group type: EXPERIMENTAL
Intervention: Gadobutrol (1 mol/L) injected IV at doses of 0.1 or 0.3 mmol/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gadobutrol (1 mol/L) injected IV
Number of subjects: 11
Study: 9690266

Group type: EXPERIMENTAL
Intervention: Succimer (up to three 26-day courses)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo (up to three 26-day courses)
Number of subjects: 780
Study: 8015129

Group type: EXPERIMENTAL
Intervention: English version of the manuscript
Number of subjects: 180

Group type: COMPARATOR
Intervention: National-language version of the manuscript
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Referee experience
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Referee age
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Referee gender, specialty, or nationality
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Free-text comments
Number of subjects: 180
Study: 2660319

Group type: EXPERIMENTAL
Intervention: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA) in patients receiving OAC.
Number of subjects: 40
Study: 31776061

Group type: EXPERIMENTAL
Intervention: Modified OK lens design (Test) with reduced back optic zone diameter and altered asphericity and intermediate lens curves.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard OK lens design (Control).
Number of subjects: 16
Study: 31136070

Group type: COMPARATOR
Intervention: Zero dose of antibiotic prophylaxis (ABP)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Single dose of ABP (30 min before surgery)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Two doses of ABP (first dose at 30 min before RIRS and additional dose within 6 h after RIRS)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Zero dose of ABP
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Single dose of ABP
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Two doses of ABP
Number of subjects: 426
Study: 28553988

Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous acetaminophen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous acetaminophen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 20 mg/kg intravenous acetaminophen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 59
Study: 26624214

Group type: EXPERIMENTAL
Intervention: 8-week Mediterranean dietary intervention
Number of subjects: 11
Study: 23648697

Group type: EXPERIMENTAL
Intervention: High-gluten diet (16 g gluten/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-gluten diet (2 g gluten/d and 14 g whey protein/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control diet (16 g whey protein/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Gluten diet (16 g/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Whey diet (16 g/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no additional protein)
Number of subjects: 37
Study: 21605502

Group type: EXPERIMENTAL
Intervention: High-GI evening meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-GI evening meal
Number of subjects: 14
Study: 19701463

Group type: EXPERIMENTAL
Intervention: Obesity hypoventilation syndrome (OHS)
Number of subjects: 53
Study: 17446974

Group type: EXPERIMENTAL
Intervention: Manual-based psychotherapies for substance use disorder (SUD)
Number of subjects: 428
Study: 14978601

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and resistance training (400 Kcal, 15 g protein, 50% of vitamin DRVs per day, two sessions per week)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and resistance training
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nutritional supplementation only
Number of subjects: 101

Group type: COMPARATOR
Intervention: Resistance training only
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (without supplementation nor training)
Number of subjects: 101
Study: 15288708

Group type: EXPERIMENTAL
Intervention: High concentration of AND (0.00625 M) in women
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High concentration of AND (0.00625 M) in men
Number of subjects: 60
Study: 10665519

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic suspension (Azopt) t.i.d. in addition to timolol 0.5% b.i.d.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo t.i.d. in addition to timolol 0.5% b.i.d.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% t.i.d.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 132
Study: 9046703

Group type: EXPERIMENTAL
Intervention: Behavior management program with written cuing procedures implemented by trained caregivers during 12 weekly home visits.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Behavior tracking by matched control caregivers.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Behavior management program with written cuing procedures.
Number of subjects: 14
Study: 8443029

Group type: EXPERIMENTAL
Intervention: Quinapril up to 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atenolol up to 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atenolol up to 100 mg in combination with hydrochlorothiazide 25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3097384

Group type: EXPERIMENTAL
Intervention: Glibenclamide (1 tablet Euglucon N) + Insulin infusion (22 U human insulin/patient for 45 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo + Insulin infusion (22 U human insulin/patient for 45 min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glibenclamide + Insulin infusion
Number of subjects: 8
Study: 29893947

Group type: EXPERIMENTAL
Intervention: Siblings Coping Together intervention (n=41)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (n=34) with games and crafts only
Number of subjects: 75
Study: 26799345

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CS) combined with topical agents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cyclosporine (CS) monotherapy
Number of subjects: 60
Study: 24764674

Group type: EXPERIMENTAL
Intervention: Esomeprazole therapy (20 mg esomeprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole therapy (30 mg lansoprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole therapy
Number of subjects: 0